JTO Clinical and Research Reports, January 2024, Volume 5, Issue 1
Journal | English
Image For Activity Cover
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered
Table of Contents

Original Articles:
  • Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
    •  
  • Quantifying Interrater Agreement and Reliability Between Thoracic Pathologists: Paradoxical Behavior of Cohen’s Kappa in the Presence of a High Prevalence of the Histopathologic Feature in Lung Cancer
    •  
  • A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLC
    •  
Case Reports
  • HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report
    •  
  • Squamous Cell Carcinoma of the Lung With Microsatellite Instability in a Patient With Lynch Syndrome: A Case Report
    •  
  • The First Case Report of Effective Treatment With Sotorasib for Metastatic Atypical Lung Carcinoid Harboring KRAS G12C Mutation and Aggressive Disseminated Lung Metastasis: A Case Report
    •  
  • Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report
    •  
Brief Reports
  • The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors
    •  
  • The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNA T790M Testing—Patient’s Willingness-to-Pay: A Brief Report
    •  
JTO Clinical and Research Reports is the official open access journal of the International Association for the Study of Lung Cancer. It aims to complement the Journal of Thoracic Oncology by offering authors a gold open access publication option and publishing the following article types in particular:
  • Phase I trials
  • Well performed single-arm phase II trials
  • Subset analyses of published trials
  • Impactful retrospective Studies
  • Database analysis
  • Large institutional series
  • High-quality case reports
  • Region-specific clinical trials
  • Subspecialty thoracic oncology studies
  • Selected high-quality meeting reports
As an open access journal with no subscription charges, JTO CRR requires authors to pay a fee to cover the costs associated with publication. This ensures your article will be immediately and permanently free to access by everyone.
Powered By